By Tony Owusu There are reports that falling demand will necessitate an increase in prices for the company’s two breakthrough covid-19 vaccines. Governments around the world have spent tens of billions on vaccines to combat the covid-19 pandemic, and Pfizer (PFE) – Get Pfizer Inc. Report has been one of the biggest beneficiaries of that spending. While the company’s stock price is well off the highs it hit last fall, it is still nearly 40% above where it was at the start of the pandemic in March 2020. But the decline has been attributed to lower demand for the company’s pair of breakthrough co…